title: [Clinical, multicentric, and open study to evaluate the efficacy of and tolerance to sildenafil in patients with erectile dysfunction].
abstract: Erectile dysfunction (ED), defined by the Impotence-NIH Consensus Conference as the "persistent inability to achieve and/or maintain erection sufficient for satisfactory sexual activity" affect more than 100 million men worldwide, at particular severity levels. The global prevalence of ED is estimated to affect about 10%, but has been found to increase significantly with age (39% in men 40 years of age and 67% at 70 years of age). In men aged 40 to 70 years, the severe ED prevalence increased of three folds, 5 to 15%. In order to evaluate the efficacy and tolerance of sildenafil, it was conducted a national open, multicentre study on a portuguese population affected by ED. Subjects under ambulatory treatment were recruited in Psychiatry/Sexology Clinical units and Urology/Andrology. The results of the study carried out on a group of 62 men with ED, demonstrate that sildenafil was effective in the recovering of erectile function, increasing the number of attempts to sexual activity and improving their success rates (mainly in severe dysfunction). Fifty one patients treated with sildenafil, at the end of the study referred a global improvement in their erections (92.2%). Doses of 50 mg and 100 mg sildenafil were used and were well tolerated and also effective in the treatment of this pathology (70% and 69% respectively). Being this study a flexible dose one and taking into consideration that the final dose used was found the more suitable to the patients, can be concluded that 43.1% of the patients elected dose of 50 mg whereas 56.9% elected the maximum prescribed dose of 100 mg. Over and above global efficacy experimented by patients, a significant improvement in the sexual activity with partners was occurred. These results make possible a final conclusion--in the studied patients group affected by Erectile Dysfunction, aside from associated somatic pathology, sildenafil use provided a remarkable clinical profit, in what concerns global efficacy, by erectile function mechanisms improvement, concerning patients sensitivity of improvement, occurring in the major part of them, being these of high importance to the lifting up of their self-esteem.
authors.affiliation: Serviço de Psiquiatria e Urologia do Hospital de S. João, Instututo de Ciências Bimédicas, Hospital Geral de S. António, Porto.
authors.forename: A Pacheco
authors.initials: AP
authors.lastname: Palha
authors.forename: F Allen
authors.initials: FA
authors.lastname: Gomes
authors.forename: António Santinho
authors.initials: AS
authors.lastname: Martins
authors.forename: Adriano
authors.initials: A
authors.lastname: Pimenta
authors.forename: José
authors.initials: J
authors.lastname: Neves
authors.forename: Rosa
authors.initials: R
authors.lastname: Gonçalves
authors.forename: Luísa
authors.initials: L
authors.lastname: Ramos
authors.forename: Paulo
authors.initials: P
authors.lastname: Abrantes
authors.forename: António
authors.initials: A
authors.lastname: Canhão
authors.forename: Graça
authors.initials: G
authors.lastname: Santos
authors.forename: La Fuente
authors.initials: LF
authors.lastname: Carvalho
authors.forename: José
authors.initials: J
authors.lastname: Soares
authors.forename: Estevão
authors.initials: E
authors.lastname: Lima
authors.forename: Gilberto
authors.initials: G
authors.lastname: Rosa
mesh_terms: D000328:Adult; D000368:Aged; D007172:Erectile Dysfunction / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use*; D010879:Piperazines / Q000627:therapeutic use*; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones
chemical_list: D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D000068677:Sildenafil Citrate